Cogent Biosciences, Inc.
COGT
株式のランク
#3249
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
株価
$31.37
最終同期: 2026-10-20
時価総額
$5.44B
変化（1日）
4.54%
変化（1年）
97.81%
国
US
取引 Cogent Biosciences, Inc. (COGT)
カテゴリー
Healthcare
Cogent Biosciences, Inc.（COGT）の収益
Jun 2026 時点の収益 TTM: 0.00
Cogent Biosciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0.00 です。2023 年には 0.00 の収益があり、これは 2022 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cogent Biosciences, Inc. の収益履歴（2015 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | $7.87M | -65.02% |
| 2019 | $22.50M | 131.14% |
| 2018 | $9.73M | 16.44% |
| 2017 | $8.36M | 31.55% |
| 2016 | $6.36M | 112.83% |
| 2015 | $2.99M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
